My watch list
my.bionity.com  
Login  

02-07-2012: e-Therapeutics plc announced that Dr Rajesh Chopra has joined the Company’s Board as a Non-Executive Director.

A clinician and scientist by training, Dr Chopra has since 2009 been Vice President of Translational and Early Drug Development at Celgene Corporation. He leads a group of around 100 people working to integrate drug discovery and clinical development at Celgene sites in San Diego and San Francisco, CA, Summit, NJ, and Seville, Spain.

Dr Chopra has extensive experience of all phases of drug development, in drug portfolio management including acquisition of new assets, and of dealing with regulators and government agencies. Before joining Celgene, he spent five years at AstraZeneca in the US and the UK, culminating in the role of Medical Science Director, Senior Principal Scientist and Disease Area Team Leader for blood cancers. He also has a distinguished track record as a clinician, academic and scientist in the UK, including seven years as Clinical Director of the Department of Haematological Oncology at the Christie Hospital, Manchester.

Dr Chopra holds a BSc and an MBBS from University College and Middlesex School of Medicine, University of London and a PhD from the University of London. He is a Fellow of both the Royal College of Physicians and the Royal College of Pathologists in the UK.

Watchlist

This is where you can add this news to your personal favourites

More about e-Therapeutics
  • News

    Celgene Executive Dr Rajesh Chopra joins the Board of e-Therapeutics

    e-Therapeutics plc announced that Dr Rajesh Chopra has joined the Company’s Board as a Non-Executive Director. A clinician and scientist by training, Dr Chopra has since 2009 been Vice President of Translational and Early Drug Development at Celgene Corporation. He leads a group of around 1 ... more

    e-Therapeutics Appoints Daniel Elger as Chief Financial Officer

    e-Therapeutics plc announced that Dr Daniel Elger will be joining the Company and its Board as Chief Financial Officer, with immediate effect.Dr Elger, 41, was previously the VP, Marketing & Communications at cancer drug developer Antisoma plc. He joined that company in 2002 and served on i ... more

    e-Therapeutics Board appoints Stephen Self to direct development

    e-Therapeutics plc announced that Steve Self, Development Director, has agreed to join the Board as an Executive Director with immediate effect. Steve began his career in Chemistry in 1975 with The Wellcome Foundation. He held a variety of positions in both R&D and Operations before bei ... more

  • Companies

    e-Therapeutics plc

    e-Therapeutics is a pioneering network pharmacology company focused on drug discovery and development. e-Therapeutics has a broad clinical pipeline that combines mid- and late-stage pharmaceutical products with earlier stage opportunities, all addressing important market sectors and unmet ... more

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE